-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-42 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ASC-42 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details: ASC-42 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7303509 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RO-7303509 in Inflammation Drug Details:RO-7303509 is under development for the treatment of inflammation and systemic sclerosis....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ASC-41 in Non Alcoholic Fatty Liver Disease (NAFLD)Drug Details:ASC-41 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-42 in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ASC-42 in Hepatitis B Drug Details:ASC-42 is under development for the treatment of non-alcoholic steatohepatitis (NASH), primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-61 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASC-61 in Solid Tumor Drug Details: ASC-61 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-42 in Non-Alcoholic Steatohepatitis (NASH)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ASC-42 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:ASC-42 is under development for the treatment of non-alcoholic steatohepatitis (NASH), primary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – VIR-3434 in Hepatitis B
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tobevibart in Hepatitis B Drug Details: Tobevibart (VIR-3434) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7502175 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RO-7502175 in Solid Tumor Drug Details:RO-7502175 is under development for the treatment of advanced or metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986288 in Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BMS-986288 in Renal Cell Carcinoma Drug Details:BMS-986288 is under development for the treatment of advanced solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Drug Details: ALG.APV-527 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pelareorep in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Pelareorep in Pancreatic Ductal AdenocarcinomaDrug Details: Pelareorep (Reolysin) is under development for the treatment of metastatic...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
NAFLD Clinical Trials Market Report Overview The NAFLD clinical trial market research report provides an overview of the NAFLD clinical trials scenario. The report provides top-line data relating to the clinical trials on NAFLD. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
![]()
Net Present Value Model: ASC09
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model ASC09 Drug Details TMC-310911 (ASC-09) is...
-
Product Insights
![]()
Net Present Value Model: Asclevir
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Asclevir Drug Details Ravidasvir Hydrochloride (Asclevir)...
-
Product Insights
![]()
Net Present Value Model: Denifanstat
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Denifanstat Drug Details Denifanstat (TVB-2640) is...
-
Product Insights
![]()
Net Present Value Model: Ganovo
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Ganovo Drug Details Danoprevir (Ganovo) is...
-
Product Insights
![]()
Net Present Value Model: Enweida
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Enweida Drug Details Envafolimab (Enweida) is...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-61
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ASC-61 Drug Details ASC-61 is under development for the treatment of solid tumors. It...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-43F
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ASC-43F Drug Details ASC-43F is under development for the treatment of non-alcoholic steatohepatitis (NASH)...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-41
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ASC-41 Drug Details ASC-41 is under development for the treatment of nonalcoholic steatohepatitis (NASH)...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.